- Funding to Date*
BiomeSense is developing an integrated biosensor & cloud-based bioinformatics platform to massively scale the collection and analysis of gut microbiome data, producing up to 30x the data for <10% of the cost compared to conventional methods. The enabling technology is a proprietary microfluidic biosensor that’s installed in the patient home, passively and continuously sampling the gut microbiome without any input from the patient.
The company’s first market is clinical research, exponentially increasing the data available during clinical trials. After this market, the company plans to rapidly move to clinical use as a companion / traditional diagnostic, and long-term, the ultimate vision is to become a widespread consumer product to enable everyone to track and understand their microbiome for better health.